Michael Okunewitch
Stock Analyst at Maxim Group
(0.52)
# 4,178
Out of 5,149 analysts
27
Total ratings
23.08%
Success rate
-18.65%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNRX VolitionRx | Downgrades: Hold | n/a | $0.20 | - | 1 | Dec 3, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $5 → $10 | $1.38 | +624.64% | 1 | Oct 20, 2025 | |
| CTOR Citius Oncology | Upgrades: Buy | $6 | $1.06 | +466.04% | 3 | Sep 23, 2025 | |
| HCWB HCW Biologics | Maintains: Buy | $120 → $35 | $0.66 | +5,203.03% | 2 | May 29, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $4.87 | +146.66% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $16 → $28 | $1.79 | +1,461.63% | 2 | Feb 20, 2025 | |
| MYNZ Mainz Biomed | Initiates: Buy | $14 | $0.84 | +1,573.64% | 1 | Feb 14, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $1.89 | +58.73% | 1 | Jan 10, 2025 | |
| OCGN Ocugen | Initiates: Buy | $4 | $1.86 | +115.05% | 1 | Oct 15, 2024 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.39 | +2,983.25% | 1 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $6 | $0.56 | +974.88% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $12 | $0.68 | +1,677.78% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.67 | +1,337.13% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $2.02 | +791.09% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $1.88 | +107,612.77% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $17.20 | +45.35% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.21 | +2,780.46% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.69 | +577.51% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $0.74 | +13,415.34% | 1 | Nov 30, 2021 |
VolitionRx
Dec 3, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.20
Upside: -
Rani Therapeutics Holdings
Oct 20, 2025
Maintains: Buy
Price Target: $5 → $10
Current: $1.38
Upside: +624.64%
Citius Oncology
Sep 23, 2025
Upgrades: Buy
Price Target: $6
Current: $1.06
Upside: +466.04%
HCW Biologics
May 29, 2025
Maintains: Buy
Price Target: $120 → $35
Current: $0.66
Upside: +5,203.03%
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $4.87
Upside: +146.66%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $16 → $28
Current: $1.79
Upside: +1,461.63%
Mainz Biomed
Feb 14, 2025
Initiates: Buy
Price Target: $14
Current: $0.84
Upside: +1,573.64%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $1.89
Upside: +58.73%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $1.86
Upside: +115.05%
FibroBiologics
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $0.39
Upside: +2,983.25%
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $0.56
Upside: +974.88%
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $0.68
Upside: +1,677.78%
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $1.67
Upside: +1,337.13%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $2.02
Upside: +791.09%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $1.88
Upside: +107,612.77%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $17.20
Upside: +45.35%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $0.21
Upside: +2,780.46%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $3.69
Upside: +577.51%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $0.74
Upside: +13,415.34%